ReviewCurrent neurology and neuroscience reports2016
Alemtuzumab for Multiple Sclerosis.
Review in Current neurology and neuroscience reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Exploring autoimmune endocrine diseases induced by monoclonal antibodies used as multiple sclerosis pharmacotherapy: a systematic review.Naunyn-Schmiedeberg's archives of pharmacology · 2025Pooled it
- Monoclonal Antibodies in Preclinical EAE Models of Multiple Sclerosis: A Systematic Review.International journal of molecular sciences · 2017Pooled it
- Identification of potential diagnostic biomarkers of atherosclerosis based on bioinformatics strategy.BMC medical genomics · 2023Article
- Susac's syndrome as an autoimmune complication of alemtuzumab-associated immune reconstitution.Journal of neurology · 2022Article
- Loss of thymic function promotes EAE relapse in anti-CD52-treated mice.Current research in immunology · 2022Article
- Detecting and predicting neutralization of alemtuzumab responses in MS.Neurology(R) neuroimmunology & neuroinflammation · 2020Article
- Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing-Remitting Multiple Sclerosis Patients? A Narrative Review.Neurology and therapy · 2020Review
- Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis.Journal of neurology · 2019Observational
- Tissue Transglutaminase Appears in Monocytes and Macrophages but Not in Lymphocytes in White Matter Multiple Sclerosis Lesions.Journal of neuropathology and experimental neurology · 2019Article
- Immune reconstitution after alemtuzumab therapy for multiple sclerosis triggering Graves' orbitopathy: a case series.Eye (London, England) · 2019Article
- Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 2.International journal of physiology, pathophysiology and pharmacology · 2019Review
- Anti-CD52 antibody treatment depletes B cell aggregates in the central nervous system in a mouse model of multiple sclerosis.Journal of neuroinflammation · 2018Article
- CD52 glycan binds the proinflammatory B box of HMGB1 to engage the Siglec-10 receptor and suppress human T cell function.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Rescue therapy with alemtuzumab in multiple sclerosis post-natalizumab puerperium reactivation.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2018Article
- Effectiveness and safety of Rituximab in multiple sclerosis: an observational study from Southern Switzerland.PloS one · 2018Observational
- An observational study of alemtuzumab following fingolimod for multiple sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2017Article
- Visual consequences of medications for multiple sclerosis: the good, the bad, the ugly, and the unknown.Eye and brain · 2017Review
- Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis.Therapeutics and clinical risk management · 2017Review
- Secondary Autoimmune Dermatological Disorders Induced by Multiple Sclerosis Biological Immunotherapy Agents: A Systematic Review of Case Reports.Iranian journal of pharmaceutical research : IJPRArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alemtuzumab is a humanised anti-CD52 monoclonal antibody approved for use in active, relapsing multiple sclerosis (MS). Administration results in a rapid depletion of circulating lymphocytes with a subsequent beneficial immune reconstitution. Early open-label experience and recent clinical trials have demonstrated a dramatic effect on relapse rates as well as a positive effect on radiological disease outcomes and disability measures. Despite a mechanism of action that results in profound lymphopaenia, opportunistic infections are rarely seen and no excess association with malignancy has been identified. However, acquired autoimmune disease (AID) is a common adverse event following treatment, necessitating rigorous monitoring in order to facilitate prompt detection and management. Despite this issue, a unique dosing schedule and durability of effect make alemtuzumab a welcome addition to currently available treatment options for MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.